The news appears to be very good on the surface. I guess the question is will NKTR be able to succeed in OBD where ADLR's Entereg failed? I believe that Entereg succeeded in the OBD indication in Phase II but missed in Phase III and had the safety issues crop up in Phase III too. The drug eventually got approved, but in POI, a much smaller indication. I believe ADLR traded at a market cap close to $1 billion back in 2006, based on the hope of Entereg to treat OBD (it's a large market).
Market Data 
Markets 
AI
